Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
- 1 May 2009
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 181 (5) , 1998-2008
- https://doi.org/10.1016/j.juro.2009.01.047
Abstract
Purpose: Androgen deprivation therapy has a variety of well recognized adverse effects including vasomotor flushing, loss of libido, fatigue, gynecomastia, anemia and osteoporosis. This review focu...Keywords
This publication has 60 references indexed in Scilit:
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31Journal of Clinical Oncology, 2009
- Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate CancerJAMA, 2008
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III StudyJournal of Clinical Oncology, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008
- Standards of Medical Care in Diabetes—2008Diabetes Care, 2008
- The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort studyBJU International, 2006
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Journal of Clinical Oncology, 2006
- Noncancer Deaths in White Adult Cancer PatientsJNCI Journal of the National Cancer Institute, 1993